|
- What’s the latest on monoclonal antibody therapies to treat COVID-19?
Here's more information on the two monoclonal antibody therapies that the FDA recommends and criteria for their use: Sotrovimab Sotrovimab is authorized to treat mild to moderate COVID-19 in patients at high risk of hospitalization and disease progression These patients need to be 12 and older and weigh at least 88 pounds
- Monoclonal antibody treatment can help high-risk patients with COVID-19
Mayo Clinic is treating patients with COVID-19 with monoclonal antibody treatments The Food and Drug Administration (FDA) issued an emergency use authorization to use bamlanivimab and casirivimab-imdevimab to treat confirmed COVID-19 in patients who have mild or moderate symptoms, and at a high-risk of disease progression and hospitalization The treatments are given in the outpatient […]
- Mayo Clinic study finds dysfunctional white blood cells linked to . . .
A Mayo Clinic study finds that people with a condition called monoclonal B-cell lymphocytosis (MBL) have a heightened melanoma risk
- Patients treated with monoclonal antibodies during COVID-19 delta surge . . .
A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers
- Discovery’s Edge: Multiple myeloma pioneer - Mayo Clinic News Network
For more than 60 years, Robert Kyle, M D , has catalogued patient histories, archived blood samples and observed a vast number of people with plasma cell proliferative disorders His methodical examination of the data allowed him to classify these disorders into groups: Benign — monoclonal gammopathy of undetermined significance Intermediate — smoldering multiple myeloma Severe — […]
- Smoldering multiple myeloma: What it is, how it progresses and the . . .
What is smoldering multiple myeloma? The first phase of abnormal plasma cells building up in the bone marrow without causing symptoms or complications is a benign (noncancerous) condition called monoclonal gammopathy of undetermined significance (MGUS) Approximately 10% of people diagnosed with MGUS will develop multiple myeloma in their lifetime
- Monoclonal antibodies: Update on this COVID-19 experimental therapy
Monoclonal antibody drugs can be used to boost the immune system's response or calm it down They can be used alone or in combination with other monoclonal antibodies Administering a monoclonal antibody infusion to a COVID-19 positive person requires all the right personal protective equipment For the patient, that means a mask
- Study shows immune molecule may play key role in the progression of ALS
Researchers have identified a protein expressed by immune cells that may play a key role in the development of amyotrophic lateral sclerosis
|
|
|